Axial Spondylarthritis Market Size to Reach US$ 11.1 Billion by 2034, Impelled by Advancements in Early Detection

Axial Spondylarthritis Market Outlook 2024-2034:

The axial spondylarthritis market size reached a value of US$ 6.2 Billion in 2023. Looking forward, the market is expected to reach US$ 11.1 Billion by 2034, exhibiting a growth rate (CAGR) of 5.38% during 2024-2034. The market is driven by the inflating application of various pain management approaches, such as heat or cold therapy, transcutaneous electrical nerve stimulation (TENS), acupuncture, etc., because they can help alleviate pain and stiffness associated with the ailment.

Advances in Early Detection and Diagnostic Technologies: Driving the Axial Spondylarthritis Market 

Advances in early detection and diagnostic technologies are playing a pivotal role in driving growth in the axial spondyloarthritis (axSpA) market. Moreover, the widespread use of magnetic resonance imaging (MRI) has revolutionized the early detection of axSpA. Unlike X-rays, which detect structural changes only in later stages, MRI can identify inflammation in the sacroiliac joints and spine early in the disease process. This enables clinicians to diagnose axSpA before significant joint damage occurs, facilitating earlier intervention. Additionally, advancements in biomarker research are enhancing diagnostic precision. Elevated levels of C-reactive protein (CRP) and the presence of genetic markers such as HLA-B27 are increasingly used to support early diagnosis and assess disease activity. These biomarkers not only help in diagnosing axSpA but also aid in monitoring disease progression and response to therapy. Furthermore, digital health technologies, including mobile apps and wearable devices, are also emerging as valuable tools for tracking symptoms and functional limitations in real time. These innovations enable patients to report disease activity more accurately, providing clinicians with data to tailor treatments effectively. These advancements in early detection and diagnostics are expanding the axSpA market by increasing diagnosis rates, improving patient outcomes, and driving demand for targeted therapies such as TNF inhibitors and IL-17 inhibitors.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The development of novel therapies and pharmacological treatments is significantly contributing to the expansion of the axial spondyloarthritis market, addressing the unmet needs of patients with this chronic inflammatory condition.  Moreover, biologic therapies, particularly tumor necrosis factor (TNF) inhibitors such as adalimumab and etanercept, have revolutionized axSpA management by effectively reducing inflammation and improving quality of life. These treatments have set the stage for a new wave of therapies targeting alternative pathways. Interleukin-17 (IL-17) inhibitors, such as secukinumab and ixekizumab, offer additional options, especially for patients who do not respond to or cannot tolerate TNF inhibitors. These biologics have demonstrated significant efficacy in controlling inflammation and preventing structural damage. Furthermore, the development of oral small molecules, like Janus kinase (JAK) inhibitors, represents another innovative approach. These therapies offer the convenience of oral administration and have shown promise in reducing disease activity, expanding treatment options for patients who prefer non-injectable solutions. Additionally, advances in precision medicine are driving the discovery of novel therapeutic targets based on individual patient profiles. This includes research into newer cytokines and cellular pathways involved in axSpA pathogenesis, paving the way for more personalized and effective treatments. These therapeutic advancements not only improve patient outcomes but also drive market growth by broadening the range of treatment options.

Marketed Therapies in Axial Spondylarthritis Market

Humira (Adalimumab): AbbVie 

Humira (Adalimumab) is a prescription medication used to treat the symptoms of ankylosing spondylitis in adults. Adalimumab binds specifically to tumor necrosis factor-alpha (TNF-alpha) and inhibits its interaction with the p55 and p75 cell surface TNF receptors. Humira also can directly neutralize TNF-alpha, trigger apoptosis, and inhibit cytokines.

Enbrel (Etanercept): Amgen/Pfizer

Enbrel is a type of medicine that helps relieve the joint pain and stiffness of axial spondylarthritis. The drug is a fusion protein derived from recombinant DNA. Etanercept functions as a soluble TNF receptor, binding to both TNF-alpha and TNF-beta. This stops TNF from attaching to cell surface receptors, making it physiologically inactive.

Simponi (Golimumab): Janssen Pharmaceutical Companies

Simponi (Golimumab) is a TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as ankylosing spondylitis. Golimumab is a human monoclonal antibody that suppresses both soluble and transmembrane TNFα. Inhibiting TNFα stops it from attaching to its receptors, preventing leukocyte infiltration and pro-inflammatory cytokine release in vitro.

Taltz (Ixekizumab): Eli Lilly and Company 

Taltz (Ixekizumab) is a medication used to treat adults with active ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ixekizumab is a humanized IgG4 monoclonal antibody that specifically binds to the cytokine interleukin 17A (IL-17A) and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that plays a role in normal inflammatory and immunological responses.

Rinvoq (Upadacitinib): AbbVie

Rinvoq (Upadacitinib) is a selective Janus kinase (JAK) inhibitor that is approved by the U.S. FDA for the treatment of axial spondyloarthritis. Upadacitinib works by blocking intracellular cytoplasmic enzymes JAK, a family of four tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) involved in immune-mediated inflammatory disorders. Inhibiting JAKs prevents growth factor and cytokine-mediated signals from being transduced intracellularly via the JAK-STAT pathway.

Emerging Therapies in Axial Spondylarthritis Market

Filgotinib: Galapagos NV 

Filgotinib is an oral drug that's being developed by Galapagos NV to treat axial spondyloarthritis. Filgotinib targets the JAK-STAT system by specifically reducing JAK1 phosphorylation and blocking STAT activation, resulting in reduced proinflammatory cytokine signaling. Filgotinib is readily absorbed following oral treatment.

Detailed list of emerging therapies in Axial Spondylarthritis is provided in the final report.

Leading Companies in the Axial Spondylarthritis Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global axial spondylarthritis market, several leading companies are at the forefront of developing integrated platforms to enhance the management of axial spondylarthritis. Some of the major players include Janssen Pharmaceutical Companies, Eli Lilly and Company, and AbbVie. These companies are driving innovation in the axial spondylarthritis market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for kidney injury.

​In October 2024, Johnson & Johnson (J&J) stated that it had taken over all sales, marketing, and distribution for Simponi (golimumab) and Remicade (infliximab) in the UK.

In August 2022, Eli Lilly and Company introduced a novel, citrate-free formulation of Taltz (ixekizumab) injection at 80 mg/mL. The new formulation, approved by the United States Food and Drug Administration in May 2022, contains the same active component as the original formulation. The new Taltz formulation significantly decreased injection site pain felt by some persons shortly after administration.

In July 2022, AbbVie announced that the European Commission approved RINVOQ (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation, as indicated by elevated C-reactive protein and/or magnetic resonance imaging, and who have responded inadequately to nonsteroidal anti-inflammatory drugs.

Key Players in Axial Spondylarthritis Market:

The key players in the Axial Spondylarthritis market who are in different phases of developing different therapies are AbbVie, Amgen, Pfizer, Janssen Pharmaceutical Companies, Eli Lilly and Company, Galapagos NV, and Others

Regional Analysis:

The major markets for axial spondylarthritis include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for axial spondylarthritis while also representing the biggest market for its treatment. This can be attributed to the rising prevalence of the disease, advancements in diagnostic tools, and the development of novel therapeutic options.

Moreover, greater awareness among healthcare providers and improved diagnostic criteria have led to earlier and more accurate diagnoses, expanding the patient pool eligible for treatment. Additionally, numerous advancements in imaging technologies, particularly MRI, have been crucial in detecting the condition at earlier stages, even before structural damage is visible on X-rays. This has allowed for timely initiation of treatment, improving patient outcomes and driving demand for therapeutic interventions.

Besides this, the recent development of oral small molecule therapies, such as Janus kinase inhibitors, offers additional options, catering to patient preferences for non-injectable treatments​.

Recent Developments in Axial Spondylarthritis Market:

• In April 2023, Galapagos NV announced that the first patient was randomized in OLINGUITO, the pivotal Phase 3 program of filgotinib in axial spondyloarthritis. OLINGUITO Phase 3 program in adults with axial spondyloarthritis to include two parallel studies to investigate the efficacy and safety of filgotinib in patients with active radiographic axial spondyloarthritis and non-radiographic axial spondyloarthritis.
   

Key information covered in the report.

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

 Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the axial spondylarthritis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the axial spondylarthritis market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report offers a comprehensive analysis of current axial spondylarthritis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

 Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800